ITC Seeks Comments on Section 337 Complaint on Photodynamic Therapy Devices, Drugs
The International Trade Commission seeks comments by July 10 on a Section 337 complaint filed by Sun Pharmaceutical Industries seeking a ban on photodynamic therapy systems and associated pharmaceuticals from Biofrontera that allegedly infringe on its patents. In its June…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
26 complaint, Sun said Biofrontera’s BF-RhodoLED XL and Ameluz prescription medicines infringe on patents related to Sun’s Blu-U Blue Light Photodynamic Therapy Illuminator device and its Levulan medication. The devices are used “particularly” to treat dermatological conditions, Biofrontera said. The company seeks a limited exclusion order and cease and desist orders banning importation and sale of infringing devices and drugs from Biofrontera.